Latest news with #WangLi
The Hindu
16-06-2025
- Business
- The Hindu
Lupin, China's SUP ink pact for COPD drug Tiotropium DPI
Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for commercialisation of chronic obstructive pulmonary disease drug Tiotropium Dry Powder Inhaler, 18 mcg/capsule, in the Chinese market. Under the partnership that will enable Lupin to expand footprint in China, SUP will obtain regulatory approvals for selling Tiotropium DPI in China. Lupin will be the marketing authorisation holder and responsible for manufacturing of the product. Tiotropium DPI is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions. Their partnership comes in backdrop of increasing prevalence of respiratory conditions, Lupin said in a release on Monday. 'This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector,' Lupin's President of Corporate Development Fabrice Egros said. SUP president Wang Li said 'by bringing more efficient and superior products to market, we aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health.' Lupin shares closed with a gain of less than 1% on the BSE at ₹2,010.55 each on Monday.
Business Standard
16-06-2025
- Business
- Business Standard
Lupin inks licensing deal with Sino Universal pharma for Tiotropium DPI drug in China
Lupin announced that it has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for the commercialization of Tiotropium Dry Powder Inhaler (DPI) capsules in China for the treatment of chronic obstructive pulmonary disease. As per the agreement, SUP will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the marketing authorization holder and responsible for manufacturing the product. Tiotropium DPI is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions. This partnership will enable Lupin to expand its footprint in China, ensuring that patients have timely access to innovative and high-quality healthcare solutions, considering the increasing prevalence of respiratory conditions. Fabrice Egros, president of corporate development, Lupin, said, "We are very pleased to partner with SUP to bring Tiotropium DPI to patients in China. This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector. SUP is our esteemed partner in this endeavor, and together we aim to enhance patient access to innovative and high-quality healthcare solutions. Wang Li, president of SUP, said, "We are truly honored to partner with Lupin, a global pharmaceutical leader, on Tiotropium DPI. Lupin's deep commitment to respiratory disease treatment and its innovation-driven approach to high-quality products align perfectly with SUP's strategic vision. We believe this collaboration will strengthen our synergy in respiratory care. By bringing more efficient and superior products to market, we aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health." Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.05% to Rs 2,001.45 on the BSE.
&w=3840&q=100)
Business Standard
16-06-2025
- Business
- Business Standard
Lupin, Sino Universal sign agreement to launch Tiotropium DPI in China
Lupin Limited on Monday entered into a licence and supply agreement with Sino Universal Pharmaceuticals (SUP) to launch Tiotropium Dry Powder Inhaler (DPI), 18 mcg per capsule, in the Chinese market, according to a BSE filing by the company. Tiotropium DPI is used to treat chronic obstructive pulmonary disease (COPD). As part of the agreement, SUP will be responsible for securing regulatory approvals in China to sell the Tiotropium DPI. Meanwhile, Lupin will hold the marketing authorisation and manage the product's manufacturing. Focus on COPD treatment and access Tiotropium DPI is recognised for its ability to help patients with respiratory diseases by improving lung function and quality of life. This partnership supports Lupin's efforts to widen its reach in China, ensuring people have timely access to effective and reliable healthcare treatments, particularly as respiratory illnesses rise. Wang Li, President of SUP, added, "We are truly honoured to partner with Lupin, a global pharmaceutical leader, on Tiotropium DPI. Lupin's deep commitment to respiratory disease treatment and its innovation-driven approach to high-quality products align perfectly with SUP's strategic vision. We believe this collaboration will strengthen our synergy in respiratory care. By bringing more efficient and superior products to market, we aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health." Lupin Limited, headquartered in Mumbai, India, is a global pharmaceutical company focused on a wide range of products, including branded and generic medicines, complex generics, biotechnology products, and active pharmaceutical ingredients. Sino Universal Pharmaceuticals, based in China, is a global one-stop pharmaceutical distribution and management service provider with over 18 years of experience.
The Star
11-06-2025
- Business
- The Star
Chinese firm to undertake Lao agriculture and forestry development project
Bouachanh Sihavong (right) and Wang Li signing agreement on transport and road development. - VT VIENTIANE: The State Enterprise for Agricultural Service of the Ministry of Agriculture and Forestry has signed a Memorandum of Understanding (MoU) with the Shandong Hi-Speed Road & Bridge International Engineering Co, Ltd of China. The agreement authorises the company to carry out a feasibility study of agricultural and forestry development and the processing of agricultural and forestry products along Road 1F, as well as the upgrade of the road to better facilitate the transport of agricultural goods for export. The MoU was signed in Vientiane on June 6 by the Director of the State Enterprise for Agriculture Service, Bouachanh Sihavong, and the Chairman of Shandong Hi-Speed Road & Bridge International Engineering Co, Ltd, Wang Li. Speaking at the ceremony, Bouachanh Sihavong said 'This cooperation will contribute to the transformation from traditional production models to a modern industry linked to value-added processing with the provision of production factors and services as a focus to resolve problems that have occurred in the past.' 'This includes damage caused by climate change (floods, droughts, pest infestations), high production costs, no market for products produced, the production process does not follow clean agricultural principles, the market does not accept the product, transport costs are expensive, etc.' It will also enable people living in the project area to boost their incomes by improving their farming skills so they can grow more crops on a commercial basis in a group format, supported by strong cooperatives, a good information learning system, early warning of disasters, and access to a wide range of services such as land planning, water supply, crop varieties, farming methods, maintenance, marketing information, and credit schemes, Bouachanh said. 'We have included a study of the development of freight transport in the agricultural development study project from the beginning.' 'This partnership will help to reduce the government's investment budget by attracting grants and qualified entrepreneurs to invest in infrastructure for production and processing,' he added. If the project goes according to plan, it will move forward to a higher level and the consideration of a joint venture. The results of the collaboration are expected to increase annual crop yields. It is envisaged that the rice harvest will increase by more than 500,000 tonnes, vegetable crops by more than 1,000,000 tonnes, fruit by at least 600,000 tonnes, and livestock by at least 300,000 tonnes. It is also hoped that fish farming will involve at least 500,000 more people a year, and that agricultural and forestry tourism will increase by at least 500,000 people a year, which will contribute an additional 25-30 per cent to Gross Domestic Product (GDP) from agriculture each year. 'I believe that if each of the project goals set for this study and development is achieved, it will not only contribute to the production and processing of agricultural products and generate additional income, it will also become a model of modern commercial agriculture linked to sustainable tourism with public participation,' Bouachanh said. This will involve the sharing of information, create more jobs for young people, and can be expanded to more parts of the country, he added. - Vientiane Times/ANN
South China Morning Post
01-05-2025
- Health
- South China Morning Post
United InnoMed targets Hong Kong for heart device trials after new funding
Shanghai-based medical device start-up United InnoMed plans to collaborate with medical institutions in Hong Kong on clinical studies with the aim of commercialising an artificial intelligence -driven device for treating and managing patients with heart failure. Advertisement Targeting chronic heart failure patients, the device would be a 'two-in-one' instrument serving both therapeutic and diagnostic functions, according to founder and CEO Wang Li. The firm hopes to cut the risks and costs of implanting two separate devices for such cases under most existing situations, he added. 'Many Chinese heart failure patients are willing to have a therapeutic device implanted, but most would be [opposed] to having another device lodged for real-time monitoring,' he said in an interview last week. 'Our two-in-one concept is similar to smartphones. Before they were developed, we needed a camera, a phone and a laptop to do what can be done in one device today.' So far, only two implantable monitoring devices have been approved by the US Food and Drug Administration for monitoring pulmonary pressure daily from home, he added. CEO Wang Li previously collaborated with Grantham Hospital in Wong Chuk Hang on medical research while working for Medtronic. Photo: Xiaomei Chen Hong Kong could be one of the trial sites as part of the firm's international development effort, Wang said. Advertisement 'Coming to Hong Kong to collaborate with hospitals on clinical studies for our products would be an obvious choice,' he said. 'My previous experience working with clinicians in Hong Kong was excellent, I was impressed with the data quality and high work standards.'
